|
WO2020205542A1
|
|
Microbiome byproducts and uses thereof
|
|
WO2020186190A2
|
|
Epitope-based approach for allergy treatments and inhibitors for crohn's disease
|
|
WO2020172401A1
|
|
Method and system for microbiome-derived companion diagnostics
|
|
WO2020154620A2
|
|
Antibody-dna conjugates and hpv detection and treatment
|
|
WO2020142764A1
|
|
Htra inhibitors and caga inhibitors and use thereof
|
|
KR20200132954A
|
|
Methods and systems for characterization of metabolic-related conditions, including diagnosis and therapy based on bioinformatics approaches
|
|
CN111465704A
|
|
Method and system for high-throughput particle processing by using magnetic fields and devices
|
|
US2020263171A1
|
|
Normalization for sequencing libraries
|
|
KR20200045557A
|
|
Nose-related characterization related to nasal microbiome
|
|
AU2018323974A1
|
|
Device for protecting and sealing the opening of a container
|
|
EP3676405A2
|
|
Method and system for characterization for female reproductive system-related conditions associated with microorganisms
|
|
KR20200052298A
|
|
Targeted drugs related to trimethylamine and / or trimethylamine N-oxide
|
|
KR20200054203A
|
|
Disease-related microbiome characterization process
|
|
AU2018288849A1
|
|
Method and system for library preparation with unique molecular identifiers
|
|
EP3769321A1
|
|
Method and system for characterizing microorganism-associated sleep-related conditions
|
|
EP3790889A2
|
|
Therapeutic & diagnostics compositions targeting toll-like receptors and methods thereof
|
|
EP3776285A1
|
|
Method and system for characterizing microorganism-related conditions
|
|
EP3768851A1
|
|
Method and system for characterizing diet-related conditions
|
|
EP3775257A1
|
|
Method and system for characterizing allergy-related conditions associated with microorganisms
|
|
US2017308669A1
|
|
Method and system for microbial pharmacogenomics
|
